Efficacy of Nivolumab in patient with non-small-cell lung cancer, after they had received different first line chemotherapy regimens.
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.